Connect Biopharma Q1 FY26 net loss widens to $19.4 million

• Connect Biopharma posted a net loss of USD 19.4 million, or USD 0.34 per share, for the three months ended March 31, 2026, widening from a loss of USD 10.3 million, or USD 0.19 per share, a year earlier.
• Research and development expense more than doubled to USD 15 million, while general and administrative expense was little changed at USD 4.7 million.
• Revenue was USD 0.2 million, compared with no revenue a year earlier, tied to the upfront license fee under the Simcere agreement.
• Cash and cash equivalents totaled USD 46 million; Connect expects cash and investments to fund operations into the second half of 2027.
• Phase 2 Seabreeze STAT asthma and COPD studies remained on track after an independent DMC review; topline data from both studies is expected mid-2026, following a USD 20.2 million private placement that closed March 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605120900PRIMZONEFULLFEED9717965) on May 12, 2026, and is solely responsible for the information contained therein.